Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MMP9 | P14780 | 8/20 | 0.43 |
| ▸ | MMP2 | P08253 | 7/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 6/20 | 0.42 |
| ▸ | MMP8 | P22894 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294163 | 0.79 | MMP2 (0.39) | LMNAMMP9MMP2MMP3MMP13 | |
| SCHEMBL1683293 | 0.79 | LMNA (0.58) | LMNAMMP9MMP2MMP3MMP13 | |
| SCHEMBL2850139 | 0.77 | MMP2 (0.45) | LMNAMMP9MMP2MMP3MMP13 | |
| SCHEMBL11256550 | 0.76 | MMP13 (0.43) | LMNAMMP9MMP2MMP3MMP13 | |
| Butethal SCHEMBL44262 | 0.76 | LMNA (0.67) | LMNAMMP9MMP2MMP3MMP13 | |
| SCHEMBL5272059 | 0.76 | LMNA (0.43) | LMNAMMP9MMP2MMP3MMP13 | |
| SCHEMBL11273946 | 0.76 | MMP13 (0.43) | LMNAMMP9MMP2MMP3MMP13 | |
| SCHEMBL8415310 | 0.75 | LMNA (0.59) | LMNAMMP9MMP2MMP3MMP8 | |
| SCHEMBL11109611 | 0.75 | MMP9 (0.49) | LMNAMMP9MMP2MMP3MMP13 | |
| Butethal SCHEMBL2718536 | 0.74 | LMNA (0.64) | LMNAMMP9MMP2MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250418-A1 | MIXTURE FOR INHIBITING THE EMISSION OF ALDEHYDES FROM POLYURETHANE FOAM FOR AN EXTENDED PERIOD OF TIME | HUNTSMAN PETROCHEMICAL LLC | 2025-08-07 | — | — | US | claimed |
| EP-4508111-A1 | MIXTURE FOR INHIBITING THE EMISSION OF ALDEHYDES FROM POLYURETHANE FOAM FOR AN EXTENDED PERIOD OF TIME | Huntsman Petrochemical LLC (US) | 2025-02-19 | — | — | EP | claimed |
| WO-2023200641-A1 | MIXTURE FOR INHIBITING THE EMISSION OF ALDEHYDES FROM POLYURETHANE FOAM FOR AN EXTENDED PERIOD OF TIME | HUNTSMAN PETROCHEMICAL LLC (US) | 2023-10-19 | — | — | WO | claimed |
| EP-1387659-B1 | INITIATOR SYSTEM FOR ACID DENTAL FORMULATIONS | 3M ESPE AG (DE) | 2008-05-07 | — | — | EP | claimed |
| US-20250250418-A1 | MIXTURE FOR INHIBITING THE EMISSION OF ALDEHYDES FROM POLYURETHANE FOAM FOR AN EXTENDED PERIOD OF TIME | HUNTSMAN PETROCHEMICAL LLC | 2025-08-07 | — | — | US | disclosed |
| EP-4508111-A1 | MIXTURE FOR INHIBITING THE EMISSION OF ALDEHYDES FROM POLYURETHANE FOAM FOR AN EXTENDED PERIOD OF TIME | Huntsman Petrochemical LLC (US) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023200641-A1 | MIXTURE FOR INHIBITING THE EMISSION OF ALDEHYDES FROM POLYURETHANE FOAM FOR AN EXTENDED PERIOD OF TIME | HUNTSMAN PETROCHEMICAL LLC (US) | 2023-10-19 | — | — | WO | disclosed |
| US-9937106-B2 | Kit of parts, method of producing and use thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170056299-A1 | KIT OF PARTS, METHOD OF PRODUCING AND USE THEREOF | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2017-03-02 | — | — | US | disclosed |
| EP-2598101-B1 | KIT OF PARTS, METHOD OF PRODUCING AND USE THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2017-01-25 | — | — | EP | disclosed |
| US-9498313-B2 | Kit of parts, method of producing and use thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-11-22 | — | — | US | disclosed |
| US-9144626-B2 | Paste for producing bone cement | HERAEUS MEDICAL GMBH (DE) | 2015-09-29 | — | — | US | disclosed |
| US-8791172-B2 | Three-component bone cement | HERAEUS MEDICAL GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20130143176-A1 | KIT OF PARTS, METHOD OF PRODUCING AND USE THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-06-06 | — | — | US | disclosed |
| EP-2598101-A1 | KIT OF PARTS, METHOD OF PRODUCING AND USE THEREOF | 3M Innovative Properties Company (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015814-A1 | KIT OF PARTS, METHOD OF PRODUCING AND USE THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
| EP-2412361-A1 | Kit of parts, method of producing and use thereof | 3M Innovative Properties Company (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110183932-A1 | THREE-COMPONENT BONE CEMENT | HERAEUS MEDICAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-6953535-B2 | Initiator system for acid dental formulations | 3M ESPE AG (DE) | 2005-10-11 | — | — | US | disclosed |
| US-20040097613-A1 | Initiator system for acid dental formulations | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056299-A1 | KIT OF PARTS, METHOD OF PRODUCING AND USE THEREOF | KIT, C9, F13B | LMNA 625/4885MMP9 583/4885MMP2 510/4885 |
| US-20130143176-A1 | KIT OF PARTS, METHOD OF PRODUCING AND USE THEREOF | KIT, C9, F13B | LMNA 540/4885MMP9 754/4885MMP2 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.